• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Dyadic International Inc. filed SEC Form 8-K: Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits

    6/2/25 4:50:35 PM ET
    $DYAI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $DYAI alert in real time by email
    dyai20250602_8k.htm
    false 0001213809 0001213809 2025-05-29 2025-05-29
    --12-31
     
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     

     
    FORM 8-K
     

     
    CURRENT REPORT
    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
    Date of Report (date of earliest event reported): May 29, 2025
     

     
    Dyadic International, Inc.
    (Exact name of registrant as specified in its charter)
     

     
     
    Delaware 000-55264 45-0486747
    (State or other jurisdiction of incorporation or organization) (Commission File Number) (I.R.S. Employer Identification Number)
     
    1044 North U.S. Highway One, Suite 201
    Jupiter, FL 33477
    (Address of principal executive offices and zip code)
     
    (561) 743-8333
    (Registrant’s telephone number, including area code)
     
    N/A
    (Former Name or Former Address, if Changed Since Last Report)
     
    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
     
     
    ☐
    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
     
    ☐
    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
     
    ☐
    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
     
    ☐
    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
     
     
    Securities registered pursuant to Section 12(b) of the Act
     
    Title of each class
    Trading Symbol(s)
    Name of each exchange on which registered
    Common Stock, par value $0.001 per share
    DYAI
    The Nasdaq Stock Market LLC
     
    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
    Emerging growth company ☐
     
    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
     
     

     
     
    Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
     
    On May 29, 2025, the board of directors (the “Board”) of Dyadic International, Inc. (the “Company”) appointed Joseph Hazelton as President of the Company. Mr. Hazelton, who joined the Company in 2021, will also continue to serve as its Chief Operating Officer, and Mark A. Emalfarb will continue to serve as Chief Executive Officer and as a member of the Board.
     
    Mr. Hazelton’s biography is included in the Company’s definitive proxy statement on Schedule 14A filed with the Securities and Exchange Commission on April 29, 2025. Mr. Hazelton has no family relationship with any of the Company’s directors or executive officers, and no direct or indirect material interest in any related person transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K. There are no arrangements or understandings between Mr. Hazelton and any other person pursuant to which he was appointed as President of the Company.
     
    In connection with Mr. Hazelton’s promotion, the Board approved an increase to his 2025 base salary of approximately 10% to $320,000, and a stock option grant for 2025 of 25,000 shares, which have a ten-year term, subject to earlier expiration upon termination, and vest annually in equal installments over four years on each anniversary of the grant date, subject to continued service on each vesting date. No other changes were made to Mr. Hazelton’s existing employment agreement, which provides for an annual bonus of up to 30% of his base salary, and an annual stock option award made at the discretion of the Board based on Mr. Hazelton’s performance.
     
    Item 5.03. Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.
     
    On May 29, 2025, the Board amended and restated the Company’s Third Amended and Restated Bylaws (as amended and restated, the “Bylaws”), effective immediately. Among other things, the amendments relate to (i) clarifying the role of the inspectors of election at stockholder meetings pursuant to the Delaware General Corporation Law, (ii) clarifying the procedures for virtual meetings of stockholders, (iii) clarifying and modernizing the provisions around the list of stockholders made available before stockholder meetings, (iv) updating and streamlining the provisions related to the officers of the corporation, (v) updating and streamlining the provisions related to meetings of board committees and (vi) making certain other immaterial clarifying and/or conforming changes.
     
    The foregoing summary of the Bylaws does not purport to be a complete description and is qualified in its entirety by reference to the full text of the Bylaws, a copy of which is attached hereto as Exhibit 3.1 and incorporated herein by reference. Additionally, a copy of the Bylaws that is marked to show changes to the original bylaws (additions are underlined and deletions are struck through), is also attached hereto as Exhibit 3.2 and incorporated herein by reference.
     
    Item 7.01. Regulation FD Disclosure.
     
    On June 2, 2025, the Company issued a press release regarding the appointment of Mr. Hazelton as President. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
     
    The information in Item 7.01 of this Current Report on Form 8-K, including the information set forth in Exhibit 99.1, is furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of such section. Such information shall not be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
     
    Item 9.01. Financial Statements and Exhibits.
     
    (d) Exhibits
     
     
    Exhibit
    Number
    Description
         
      3.1 Fourth Amended and Restated Bylaws of Dyadic International, Inc., effective May 29, 2025.
      3.2 Fourth Amended and Restated Bylaws of Dyadic International, Inc., effective May 29, 2025 (marked).
      99.1 Press Release dated June 2, 2025.
      104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
     
     

     
     
    SIGNATURES
     
    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
     
    Date: June 2, 2025
     
    Dyadic International, Inc.
    By:
    /s/ Ping Rawson
    Name: 
    Ping Rawson
    Title: 
    Chief Financial Officer
     
     
    Get the next $DYAI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $DYAI

    DatePrice TargetRatingAnalyst
    10/23/2025$3.00Buy
    H.C. Wainwright
    9/8/2025Buy
    Craig Hallum
    7/18/2022Buy → Neutral
    Dawson James
    12/17/2021$7.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $DYAI
    SEC Filings

    View All

    SEC Form 8-K filed by Dyadic International Inc.

    8-K - DYADIC INTERNATIONAL INC (0001213809) (Filer)

    3/27/26 9:56:17 PM ET
    $DYAI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Dyadic International Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - DYADIC INTERNATIONAL INC (0001213809) (Filer)

    3/25/26 4:14:00 PM ET
    $DYAI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 10-K filed by Dyadic International Inc.

    10-K - DYADIC INTERNATIONAL INC (0001213809) (Filer)

    3/25/26 4:13:15 PM ET
    $DYAI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $DYAI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    VP of Research and Bus. Dvlpmt Tchelet Ronen was granted 18,064 shares, increasing direct ownership by 55% to 50,897 units (SEC Form 4)

    4 - DYADIC INTERNATIONAL INC (0001213809) (Issuer)

    1/6/26 6:12:29 PM ET
    $DYAI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Financial Officer Rawson Ping Wang was granted 29,158 shares, increasing direct ownership by 21% to 170,151 units (SEC Form 4)

    4 - DYADIC INTERNATIONAL INC (0001213809) (Issuer)

    1/6/26 6:11:42 PM ET
    $DYAI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Lucy Patrick K. converted options into 21,552 shares, increasing direct ownership by 42% to 72,311 units (SEC Form 4)

    4 - DYADIC INTERNATIONAL INC (0001213809) (Issuer)

    1/6/26 6:10:38 PM ET
    $DYAI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $DYAI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Dyadic Announces 2025 Financial Results and Highlights Recent Company Progress

    Commercial launch of AlbuFree™ DX recombinant human albumin by Proliant Health & Biologicals using Dyadic's production platform, with Dyadic eligible to receive a share of profits from product salesExpanded strategic collaboration with Fermbox Bio, including the launch of animal-origin-free recombinant DNase I (RNase-free) as the first commercialized product under the expanded partnershipSigned an OEM distribution agreement with IBT Bioservices to commercialize Dyadic's recombinant DNase I and transferrin for research and cell culture applications through IBT's global distribution channelsEntered a development and commercialization agreement with BRIG Bio to produce animal-free bovine alpha-

    3/25/26 4:51:29 PM ET
    $DYAI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Dyadic Applied BioSolutions Announces Commercial Distribution Partnership with IBT Bioservices

    JUPITER, Fla., March 16, 2026 (GLOBE NEWSWIRE) -- Dyadic Applied BioSolutions ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ:DYAI), a global biotechnology company producing precision-engineered, animal-free proteins and enzymes for life science, food and nutrition, and bioindustrial applications today announced that it has entered into an original equipment manufacturer ("OEM") distribution agreement with Integrated Biotherapeutics, LLC, d/b/a IBT Bioservices ("IBT"), a life sciences reagent manufacturer and distributor serving global research markets. Through this collaboration, Dyadic-produced recombinant protein products will be commercialized through IBT's established sales ch

    3/16/26 7:20:00 AM ET
    $DYAI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing

    NEW YORK, March 13, 2026 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced that presentations from the Life Sciences Virtual Investor Forum, held March 11th – 12th, are now available for on-demand viewing. The forum featured CEO chats and company presentations from leadership teams representing innovative companies across the biotechnology, medical device, and pharmaceutical sectors, offering investors insights into emerging technologies, strategic initiatives, and growth opportunities within the life sciences industry. REGISTER AND VIEW PRESENTATIONS HERE The presentations will be available 24/7 for 90 days. Investors,

    3/13/26 8:35:00 AM ET
    $AEMD
    $CVKD
    $DYAI
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Biotechnology: Biological Products (No Diagnostic Substances)

    $DYAI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    H.C. Wainwright resumed coverage on Dyadic International with a new price target

    H.C. Wainwright resumed coverage of Dyadic International with a rating of Buy and set a new price target of $3.00

    10/23/25 7:06:50 AM ET
    $DYAI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Craig Hallum initiated coverage on Dyadic International

    Craig Hallum initiated coverage of Dyadic International with a rating of Buy

    9/8/25 8:52:07 AM ET
    $DYAI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Dyadic International downgraded by Dawson James

    Dawson James downgraded Dyadic International from Buy to Neutral

    7/18/22 9:59:51 AM ET
    $DYAI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $DYAI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President and COO Hazelton Joseph P bought $24,700 worth of shares (26,000 units at $0.95), increasing direct ownership by 20% to 155,340 units (SEC Form 4)

    4 - DYADIC INTERNATIONAL INC (0001213809) (Issuer)

    8/5/25 5:00:10 PM ET
    $DYAI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $DYAI
    Financials

    Live finance-specific insights

    View All

    Dyadic Announces 2025 Financial Results and Highlights Recent Company Progress

    Commercial launch of AlbuFree™ DX recombinant human albumin by Proliant Health & Biologicals using Dyadic's production platform, with Dyadic eligible to receive a share of profits from product salesExpanded strategic collaboration with Fermbox Bio, including the launch of animal-origin-free recombinant DNase I (RNase-free) as the first commercialized product under the expanded partnershipSigned an OEM distribution agreement with IBT Bioservices to commercialize Dyadic's recombinant DNase I and transferrin for research and cell culture applications through IBT's global distribution channelsEntered a development and commercialization agreement with BRIG Bio to produce animal-free bovine alpha-

    3/25/26 4:51:29 PM ET
    $DYAI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Dyadic to Report 2025 Full Year Financial Results and Host Conference Call on Wednesday, March 25, 2026

    JUPITER, Fla., March 11, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. d/b/a Dyadic Applied BioSolutions ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ:DYAI), a global biotechnology company focused on the scalable production of high-value, precision engineered functional input proteins for use in life sciences, food and nutrition, and industrial biotechnology applications utilizing its proprietary gene expression platforms, today announced that it will report its financial results for the year ended December 31, 2025 and host a corporate update conference call on Wednesday, March 25, 2026. Conference Call Information Date: Wednesday, March 25, 2026 Time: 5:00 p.m. Eastern

    3/11/26 4:10:00 PM ET
    $DYAI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Dyadic to Report Third Quarter 2025 Financial Results on Wednesday, November 12, 2025

    JUPITER, Fla., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Dyadic International, Inc. d/b/a Dyadic Applied BioSolutions ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ:DYAI), a global biotechnology company focused on the scalable production of high-value, precision engineered functional input proteins for use in life sciences, food and nutrition, and industrial biotechnology applications utilizing its proprietary gene expression platforms, today announced that it will report its financial results for the second quarter 2025 and host a corporate update conference call on Wednesday, November 12, 2025. Conference Call Information Date: Wednesday, November 12, 2025 Time: 5:00 p.m. Eastern Tim

    10/29/25 7:25:00 AM ET
    $DYAI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $DYAI
    Leadership Updates

    Live Leadership Updates

    View All

    Dyadic Appoints Doug Pace to Its Executive Leadership Team

    JUPITER, Fla., Oct. 09, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ:DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet needs for effective, affordable and accessible biopharmaceutical products and alternative proteins for human and animal health, today announced the appointment of Doug Pace as Executive Vice President of Business Development. The expansion of Dyadic's management team is in response to the increased interest in the Company's microbial platforms, specifically the C1 technology for infectious disease and

    10/9/23 8:30:00 AM ET
    $DYAI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Dyadic Appoints Chief Business Officer to Executive Leadership Team

    JUPITER, Fla., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ:DYAI), a global biotechnology company focused on further improving, applying and deploying its proprietary C1-cell protein production platform to accelerate development, lower production costs and improve the performance of biologic vaccines, therapeutics and other protein based products today announced the appointment of Joe Hazelton as Chief Business Officer, effective immediately. The creation of this role supports the global commercialization of the Company's new and existing business initiatives, including corporate strategy, business and corporate develo

    11/9/21 8:30:00 AM ET
    $DYAI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $DYAI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Dyadic International Inc. (Amendment)

    SC 13G/A - DYADIC INTERNATIONAL INC (0001213809) (Subject)

    2/13/24 4:41:59 PM ET
    $DYAI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by Dyadic International Inc. (Amendment)

    SC 13G/A - DYADIC INTERNATIONAL INC (0001213809) (Subject)

    2/1/24 4:15:18 PM ET
    $DYAI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by Dyadic International Inc. (Amendment)

    SC 13G/A - DYADIC INTERNATIONAL INC (0001213809) (Subject)

    3/14/23 4:01:06 PM ET
    $DYAI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care